Citi raised the firm’s price target on Fresenius Medical (FMS) to EUR 52.50 from EUR 46.50 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Expands U.S. Rollout of 5008X CAREsystem
- Fresenius Medical Care Announces Record Dividend and Strategic Milestones at AGM
- Fresenius Medical price target raised to EUR 43 from EUR 41 at Morgan Stanley
- Fresenius Medical Care Faces FTC Probe and Sells Latin American Clinics Amidst Labor Strikes
- Fresenius Medical price target raised to $30 from $25 at Truist